3 Asian Stocks Estimated To Be Up To 43.1% Below Intrinsic Value

In This Article:

As global markets navigate a landscape of economic uncertainty and shifting policies, Asian stocks present intriguing opportunities for investors seeking value. In this environment, identifying undervalued stocks—those trading below their intrinsic value—can be a prudent strategy to potentially capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In Asia

Name

Current Price

Fair Value (Est)

Discount (Est)

Consun Pharmaceutical Group (SEHK:1681)

HK$8.87

HK$17.63

49.7%

RACCOON HOLDINGS (TSE:3031)

¥957.00

¥1890.86

49.4%

Sichuan Kexin Mechanical and Electrical EquipmentLtd (SZSE:300092)

CN¥13.10

CN¥25.69

49%

TechnoPro Holdings (TSE:6028)

¥3306.00

¥6593.98

49.9%

S Foods (TSE:2292)

¥2556.00

¥5084.09

49.7%

Bide Pharmatech (SHSE:688073)

CN¥54.00

CN¥106.91

49.5%

Takara Bio (TSE:4974)

¥866.00

¥1698.81

49%

ALUX (KOSDAQ:A475580)

₩11250.00

₩22243.70

49.4%

Kinsus Interconnect Technology (TWSE:3189)

NT$93.10

NT$182.94

49.1%

Zhejiang Juhua (SHSE:600160)

CN¥24.28

CN¥47.60

49%

Click here to see the full list of 272 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Smoore International Holdings

Overview: Smoore International Holdings Limited is an investment holding company that provides vaping technology solutions and has a market cap of HK$83.08 billion.

Operations: The company generates revenue primarily from the sale of APV and vaping devices and components, amounting to CN¥11.80 billion.

Estimated Discount To Fair Value: 13.7%

Smoore International Holdings is trading at HK$13.66, below its estimated fair value of HK$15.83, suggesting potential undervaluation based on cash flows. Earnings are forecast to grow significantly at 24.94% annually, outpacing the Hong Kong market's growth rate. However, recent financial results show a decline in net income from CNY 1,645.09 million to CNY 1,303.26 million year-over-year despite increased sales revenue to CNY 11.80 billion from CNY 11.20 billion.

SEHK:6969 Discounted Cash Flow as at Mar 2025
SEHK:6969 Discounted Cash Flow as at Mar 2025

Ningbo Sanxing Medical ElectricLtd

Overview: Ningbo Sanxing Medical Electric Co., Ltd. manufactures and sells power distribution and utilization systems both in China and internationally, with a market cap of CN¥41.34 billion.

Operations: The company generates revenue from the manufacture and sale of power distribution and utilization systems, serving both domestic and international markets.

Waiting for permission
Allow microphone access to enable voice search

Try again.